To improve conventional chemotherapeutic efficacy, a combination use of traditional medicines is effective but detailed mechanisms have been rarely elucidated. In the this study, we attempted to clarify how triptolide (PG490), an oxygenated diterpene derived from a Chinese herb, enhances the cisplatin (CDDP)-induced cytotoxicity in urothelial cancer cells. Our results showed that a combined CDDP/triptolide therapy induced apoptosis in urothelial cancer cell lines with wild-type p53, but not in those with mutant-type p53 or normal human urothelium. As the mechanism, triptolide suppressed CDDP-induced p53 transcriptional activity, leading to p21 attenuation, which promoted apoptosis via the activation of c-Jun N-terminal kinase (JNK) and Bax. We further demonstrated that the functional regulation of p53 by triptolide was mediated by an intranuclear association of p53 with glycogen synthase kinase-3b (GSK3b), which was inactivated by protein kinase C (PKC). This modulation of the PKC-GSK3b axis by triptolide was observed in a cancer-specific manner. A mouse xenograft model also showed that a combined CDDP/triptolide therapy completely suppressed tumor growth without any side effects. We expect that cancer-specific enhancement of CDDP-induced cytotoxicity with triptolide may effectively overcome the resistance to a CDDP-based conventional chemotherapy as a treatment for urothelial cancer.
Introduction
Urothelial cancers are common malignancies and significant causes of morbidity and mortality. Invasive bladder cancers are very aggressive and have poor prognosis because of metastatic recurrence after radical surgery (Nishiyama et al., 2004) . Cisplatin (CDDP)-based chemotherapy has been adopted for these advanced urothelial cancers, although the use of chemotherapy is associated with significant toxicity and provides long-term survival in only 15-20% of patients due to innate or acquired resistance to chemotherapy. To improve chemotherapeutic efficacy, it is important to identify possible targets enhancing specific cell-killing mechanisms in urothelial cancer cells.
The p53 tumor suppressor gene is one of the most investigated genes in the chemosensitivity of urothelial cancer, but previous findings have been conflicting on whether it is responsible for the resistance to the effects of CDDP-based systemic chemotherapy (Sarkis et al., 1995; Cote et al., 1997) . One of the main reasons can be explained by two distinct functions of p53 in response to DNA damage, one of which is cell-cycle arrest, mainly via p21, and the other is the induction of apoptosis via such genes as PUMA and PIG3. Previously, we demonstrated that dicoumarol, an NADPH quinone oxidoreductase 1 inhibitor, enhanced the cytotoxicity of CDDP through c-Jun N-terminal kinase (JNK) activation by the suppression of the p53-p21 pathway in urogenital cancer cells (Watanabe et al., 2006) . These findings indicated that the induction of p53-p21 in malignant cells may possibly suppress the apoptotic process, and inversely, attenuation of p21 expression may make genotoxic chemotherapeutic agents more effective by subverting the normal repair process.
Triptolide (PG490) is a diterpenoid triepoxide derived from the herb tripterygium wilfordii, which has been used as a traditional medicine in China (Kupchan et al., 1972) . Although it was considered effective in the treatment of inflammatory or autoimmune disorders by the inhibition of cytokine production Chen et al., 2000; Cibere et al., 2003) , triptolide also has an antiproliferative effect for tumor cells in vitro and in vivo (Chang et al., 2001; Jiang et al., 2001; Yang et al., 2003; Fidler et al., 2003; Miyata et al., 2005; Carter et al., 2006; Wan et al., 2006) . Among several intracellular pathways suggested to be responsible for the antiproliferative effect of triptolide, the suppression of p21 is one of the most convincing mechanisms (Chang et al., 2001; Fidler et al., 2003) but the details have never been elucidated. In this study, we demonstrated the effectiveness of triptolide to enhance CDDPinduced cytotoxicity via the modulation of p53 transcriptional activity in a cancer-specific manner, and clarified that p53 transcriptional activity was modulated through an intranuclear association of functional p53 with glycogen synthase kinase-3b (GSK3b) phosphorylated at serine 9 by protein kinase C (PKC), which suppressed p21 expression and evoked the JNKmitochondria apoptotic pathway. Furthermore, we attempted combination use of triptolide with CDDP in a mouse xenograft model of urothelial cancer cells, and demonstrated the possibility of p21 attenuation therapy with triptolide in clinical application.
Results
Triptolide enhances susceptibility to CDDP in urothelial cancer cells with wild-type p53 through the suppression of p53 transcriptional activity The effects of triptolide were analysed using human normal urothelial (HNU) cells and five urothelial cancer cell lines (RT112, RT4, TCCsup, EJ and J82). Triptolide inhibited cell proliferation in all five cancer cell lines dose-dependently within 100 nM, but in the range over 100 nM, the effect plateaued. The cell viability rates 24 h after 40 nM triptolide exposure were 85.7 ± 14.0, 76.1±4.5, 80.5±18.6, 63.1±5.9 and 77.7±23.4, 79.1 ± 4.9% in RT112, RT4, TCCsup, EJ, J82 and HNU, respectively. In this study, we used the concentration at which triptolide did not induce apoptosis on its own. Susceptibility to CDDP differed among cells; IC 50 monitored by MTT assay were 42. 1 ± 11.3, 46.9±0.8, 53.6±0.4, 109.7±13.4, 556.2±55.7 and 969 .0±106.2 mM in HNU cell, RT4, RT112, TCCsup, EJ and J82, respectively. Pretreatment with triptolide enhanced the susceptibility to CDDP dose-dependently in RT112 and RT4, which retained wild-type p53, but not in three other cell lines with mutant p53 or HNU cells at 40 nM of triptolide ( Figure 1a ). Synergic effects were not observed even when the concentration of triptolide increased to 80 nM in bladder cancer cell lines with mutant p53 (Figure 1a ). Nuclear staining with Hoechst33342 in RT112 demonstrated that pretreatment with triptolide (30 nM) induced significant apoptosis in combination with CDDP (30 mM) (60.0 ± 1.0%), compared with CDDP alone (30 mM) and triptolide alone (30 nM) (8.7±3.4 and 1.9±0.4%, respectively; Figure 1a ).
The necessity of functional p53 in the effect of triptolide was elucidated in two stable clones transfected with p53 dominant-negative mutant (p53DN) (RT112 p53DN-2 and -11). Although the antiproliferative effect of triptolide itself was not significantly changed by p53DN transfection, MTT assay demonstrated that triptolide failed to enhance the susceptibility to CDDP in both p53DN transfectants (Figure 1a) . Western blot analysis also demonstrated that the combination of CDDP and triptolide activated caspases in RT112 pCMVneo but not in RT112 p53DN-11, in which normal transcriptional function of p53 was attenuated by the dominant-negative effect (Figure 1b) . On the other hand, no significant difference was shown in the intracellular distribution of nuclear factor-kB and mRNA levels of the inhibitor of apoptosisfamily regardless of the addition of triptolide in RT112 cells (Supplementary Figure 1) . All together, these data suggested that p53 function is necessary for triptolide to enhance CDDP-induced apoptosis in urothelial cancer cells.
To investigate the effect of triptolide to p53 function, change of p53 expressions and its downstream molecules were assessed. In RT112 cells, treatment with CDDP induced p53 expression in a time-dependent manner and pretreatment with triptolide slightly increased its induction ( Figure 1c ). However, whereas CDDP induced sequentially the expressions of p21, MDM2, PUMA, pretreatment with triptolide suppressed their induction after 7 h, although there was transient induction within 7 h. Bax expression was influenced neither by CDDP nor triptolide. Semiquantitative reverse transcription-PCR demonstrated that pretreatment with triptolide suppressed the induction of mRNAs for p21/MDM2/ PUMA by CDDP in RT112 cells (Figure 1c ). The effect of triptolide on p53 transcriptional activity was further examined in KK47 cells transiently transfected by wildtype p53 expressing vector (pcDNA flag-p53). CDDP failed to induce p53 in KK47 cells, although KK47 cells have no mutation in p53 genomic sequence (Supplementary Figure 2) . In KK47 cells, transient transfection of pcDNA flag-p53 induced p21 and triptolide attenuated the expression of p21 without the suppression of p53 protein level (Figure 1d ). Taken together, these results indicated that triptolide suppressed p53 transcriptional activity without suppression of p53 protein level.
The attenuation of p21 expression by triptolide is critical to evoke CDDP-induced apoptosis via the activation of the JNK-Bax pathway As CDDP-induced apoptosis is also related to mitogenactivated protein kinase cascades (Mansouri et al., 2003) , the effects of triptolide on mitogen-activated protein kinase cascades were assessed (Figure 2a) . Although CDDP alone did not induce the phosphorylation of JNK and p38, the combination treatment of triptolide and CDDP induced the phosphorylation of JNK 7 h after treatment and it was sustained over the following 14 h period in RT112, according to the induction of apoptosis. p38 was also phosphorylated by the combination treatment, but its timing was delayed. Although treatment with triptolide alone did not induce the phosphorylation of JNK at the same concentration, the combination treatment induced Bax transactivation and released cytochrome c from mito-chondria to cytosol following JNK phosphorylation (Figure 2b ). The significance of the activation of the JNK-Bax pathway in the induction of apoptosis was confirmed with SP600125 (40 mM), a specific inhibitor of JNK1/2, or Bax Channel Blocker (10 mM), both of which apparently attenuated the apoptosis (Figure 2b ). Similar effects of SP600125 and Bax Channel Blocker were also confirmed in RT4 cells (data not shown). These results indicated that activation of the JNK-Bax pathway was necessary for the synergic effect of triptolide on CDDP.
Among several p53 downstream molecules, p21 has been reported to suppress the activation of JNK (Huang et al., 2003; Watanabe et al., 2006) . We established two stable clones of RT112 transfected with p21siRNA vector (RT112 p21siRNA-8 and -12) and investigated JNK status and susceptibility to CDDP and triptolide. These clones showed higher susceptibility to CDDP than RT112 mock, and triptolide had no significant enhancement on the apoptotic ratio (Figure 2c ). Moreover, although CDDP exposure induced p21 but not the phosphorylation of JNK in RT112 mock, JNK activation was observed in RT112 p21siRNA at the same concentration of CDDP alone (Figure 2d ). These results indicated that p21 attenuation by pretreatment with Intranuclear association of p53 with GSK3b phosphorylated at serine 9 by PKC suppresses p53 transcriptional activity p53 transcriptional activity is influenced by various factors including post-translational modifications, the interaction of cofactors and subcellular distribution (Bode and Dong, 2004; Erster et al., 2004; Coutts and La Thangue, 2005) . The phosphorylation and acetylation of p53 were induced in our condition, but there were no remarkable changes between pretreatment with triptolide and that without pretreatment ( Figure 3a) . We identified that triptolide induced a gradual increase of the total amount of intracellular GSK3b and evoked the phosphorylation at serine 9 of GSK3b (p-Ser 9 GSK3b) in combination with CDDP treatment in RT112 cells after 10.5 h. Interestingly, in combination treatment, the expression of p21 was transiently induced by 7 h and attenuated at 10.5 h following the induction of p-Ser 9 GSK3b. Immunocytochemical analysis of RT112 cells revealed that whereas p53 accumulation in the nucleus was not changed by the presence or absense of triptolide treatment, GSK3b tended to accumulate in the nucleus by combination treatment, showing the same subcellular distribution to p53 (Figure 3b ). To clarify the interaction between p53 and GSK3b, we used two-dimensional (2D) BN/SDS-polyacrylamide gel electrophoresis (PAGE). The position of two protein spots in one vertical line in a 2D BN/SDS membrane could be indicative of their presence in the same multiprotein complex (MPC) (Camacho-Carvajal et al., 2004) . The spots of p53 and GSK3b were not on the same vertical line by the treatment of CDDP alone, whereas the spot of GSK3b was shifted onto the vertical line of p53 by CDDP/triptolide combination treatment (Figure 3c ). To confirm the formation of MPC, KK47 cells transiently transfected with GSK3b and p53-expressing vector were treated with triptolide. Immunoprecipitation analysis revealed that p-Ser 9 GSK3b was coimmunoprecipitated with p53 after treatment by triptolide (Figure 3d ). This association of GSK3b with p53, triptolide using treatment, was further confirmed within PC3 cells, p53-null prostate cancer cell line containing one base-deletion at codon 138, in which triptolide suppressed the transcriptional activity of transfected wild-type p53 (Figure 3e ). Taken together, these data indicated that triptolide affects GSK3b and p53 to form MPC in the nucleus.
To elucidate the importance of p-Ser 9 GSK3b in synergic effects of triptolide and CDDP, RT112 cells were stably transfected with pSUPER neo-gfp GSK3b vector containing shRNA-targeting GSK3b. The effects of triptolide on CDDP-induced cytotoxicity were attenuated in the stable transfectant of shRNA (clone-6) ( Figure 4a ). The same result was also obtained in other clones (data not shown). Suppression of the expression of GSK3b attenuated JNK activation, and also restored the expression of p21 (Figure 4a ). On the other hand, transient transfection of GSK3b(S9A), constitutively active mutant GSK3b, with wild-type p53 into KK47 cells also restored p21 expression partially after exposure to triptolide both in RNA and protein levels, compared with control transfectant (Figure 4b ). Induction of p-Ser 9 GSK3b was similarly observed in RT4 cells treated with triptolide and CDDP, which showed synergism, but not in HNU, where no synergic effect was observed (Figure 4c ). These results indicated that the interaction between p-Ser 9 GSK3b and p53 was a key mechanism for triptolide to enhance CDDP-induced apoptosis via modulation of p53 transcriptional activity. Furthermore, we examined the synergic effect of triptolide with other chemotherapeutic agents in RT112 cells. Our results showed that triptolide had a synergic effect with doxorubicin, which induced functional p53, but not with paclitaxel, which did not induce p53 (Supplementary Figure 3) , indicating that triptolide can modulate p53 transcriptional activity under the existence of functional p53 and GSK3b, and it is not CDDP-specific.
To explore the upstream mechanisms that phosphorylated GSK3b, we evaluated the change of the phosphorylated level of PKC, one of the upstream molecules of GSK3b, and 3-phosphoinositide-dependent protein kinase 1. Interestingly, PKC was activated by combination treatment in RT4 cells although there was no remarkable change in HNU (Figure 4c ).
Moreover, there was no remarkable change in the phosphorylated level of 3-phosphoinositide-dependent protein kinase 1 both in RT4 and HNU cells. To confirm the importance of PKC as the upstream of GSK3b influenced by triptolide, the effects of GF109203x, PKC inhibitor, or LY294002, phosphatidylinositol-3 kinase inhibitor, were assessed in RT112 cells. The results showed that, although inhibition of phosphatidylinositol-3 kinase by LY294002 did not influence the phosphorylation of GSK3b, inhibition of PKC by GF109203x diminished GSK3b phosphorylation and restored p21 expression, resulting in suppression of apoptosis (Figure 4d ). The effect of PKC inhibition was also shown using other PKC inhibitors, Go¨6983 and Go¨6976 (Figure 4d) . Furthermore, we confirmed that triptolide enhanced CDDP-induced cytotoxicity in cancer cells of other organs (MCF7, breast cancer cell line, and U2OS, osteosarcoma cell line) as same as urothelial cancer cells but did not show a chemosensitizing effect in human normal fibroblast (Supplementary Figure 4) . These data indicated that the intracellular target of triptolide was the PKC-GSK3b axis and that the difference in the regulation of PKC activity between human normal cells and cancer cells caused the difference in response to triptolide.
Triptolide effectively enhances CDDP-induced cytotoxicity in mouse in vivo model
For the clinical use of triptolide for urothelial carcinomas, we examined the effects of triptolide alone or in combination with CDDP to the in vivo growth of RT112 cells, using a subcutaneous xenograft model. CDDP was given weekly but triptolide was four times per week due to the short half-life of triptolide (Figure 5a ). To investigate the safety of this combination, body weight was assessed. During the treatment duration, combination treatment of CDDP and triptolide did not have an adverse effect on body weight in comparison with CDDP or triptolide alone. In our conditions, triptolide or CDDP only partially delayed tumor cell growth on its own and the tumor grew steadily, but their combination suppressed tumor growth almost completely (Figure 5a ). Hematoxylin and eosin staining of tumors demonstrated that combination treatment of triptolide and CDDP remarkably induced apoptosis, compared with CDDP treatment alone. Furthermore, immunohistochemistry revealed that JNK phosphorylation was highly promoted by the combination of CDDP and triptolide (Figure 5b ). These results indicated that triptolide could also enhance CDDP-induced cytotoxicity via JNK activation in vivo as well as in vitro.
Discussion
Triptolide, a diterpenoid triepoxide derived from the herb tripterygium wilfordii, has been reported to have an antiproliferative effect against a broad spectrum of tumors ( Fidler et al., 2003; Yang et al., 2003; Miyata et al., 2005; Yinjun et al., 2005; Carter et al., 2006; Wan et al., 2006) . Its high antiproliferative efficiency is attractive for clinical applications, and phase É clinical trials using PG490-88, a water-soluble prodrug of triptolide, have been already attempted in Europe. However, as Shamon et al. (1997) reported using a xenograft model, its narrow therapeutic window would be a problem when used as a single agent, and therefore the benefit of the combination use of triptolide at low concentrations with conventional chemotherapeutic agents such as doxorubicin and CPT-11 has been intended (Fidler et al., 2003; Carter et al., 2006) . In this study, we demonstrated the usefulness of triptolide at subtoxic concentrations to enhance CDDP-induced cytotoxicity in urothelial cancer cells with wild-type p53, without synergic toxicity to normal urothelium.
Triptolide-mediated enhancement of CDDP cytotoxicity Y Matsui et al
Although several intracellular pathways such as the modification of nuclear factor-kB, Bcl-2, phosphatidylinositol-3 kinase, cyclins and c-myc have been reported to be responsible for the mechanisms underlying the action of triptolide (Lee et al., 1999; Chang et al., 2001; Jiang et al., 2001; Fidler et al., 2003; Yang et al., 2003; Miyata et al., 2005; Yinjun et al., 2005; Carter et al., 2006; Wan et al., 2006) , our results showed that the attenuation of p53-dependent p21 induction was a key mechanism to enhance CDDP-induced cytotoxicity. Several recent studies have demonstrated that p53-dependent p21 induction inhibits the apoptotic response, and p21 attenuation may make genotoxic chemotherapeutic agents more effective by subverting the normal repair process or, more directly, by promoting the apoptotic process through inhibition of p21 interaction with apoptosis signal-regulating kinase 1, which is upstream of JNK (Asada et al., 1999; Gartel and Tyner, 2002; Weiss, 2003) . In our condition, CDDP/triptolide combination attenuated p53 downstream molecules such as p21, MDM2 and Puma which have short half-lives for mRNA and protein, but had no remarkable influence on the expression of Bax, which has relatively longer half-life, and activated JNK evoked mitochondrial apoptosis using Bax transactivation as a proapoptotic mediator. Previously, flavopiridol, a transcriptional inhibitor, showed a similar change of p53-p21 by downregulating thousands of mRNAs that have a short half-life (Demidenko and Blagosklonny, 2004) . However, as triptolide had no suppressive effect on transcription of XIAP and CIAP2 (Supplementary Figure 1 ) and slightly increased p53 protein level, we consider that triptolide functioned by modulating p53 transcriptional activity but not as a pantranscriptional inhibitor such as flavopiridol. The increase of p53 protein level after combination treatment may be due to the suppression of MDM2 protein level or upregulation of intracellular reactive oxygen species by CDDP/triptolide. 30 mM CDDP treatment did not evoke apoptosis in RT112 p53DN cells, although they already lost p21 inducibility. We propose that this is because we used stable transfectants in our experiments, and some undetermined change during clonal selection may bias cell viability.
Concerning the detailed mechanism of triptolide to modulate p53 transcriptional activity, Chang et al. (2001) previously reported that the phosphorylation of p53 induced by triptolide may be responsible. Our results, however, showed that intranuclear association of p53 with inactive p-Ser 9 GSK3b was responsible for suppressing p53 transcriptional activity. Recent studies revealed that nuclear GSK3b directly associated with p53 after DNA damage, and that its activity was necessary for full transcriptional activity of p53, whereas inhibition of GSK3b reduces the expression of p53-regulated proteins (Watcharasit et al., 2002 (Watcharasit et al., , 2003 . Although it is still controversial whether the reduction of GSK3b activity inhibits p53-induced apoptosis or contributes to promoting apoptosis via its association with p53 in nuclei or mitochondria (Watcharasit et al., 2003; Tan et al., 2005) , our results showed that inhibition of p53 transcriptional activity by inactive p-Ser 9 GSK3b in nuclei contributed to promote apoptosis under the existence of genotoxic stress of chemotherapeutic agents. Concerning the regulation of binding of GSK3b to p53, GSK3b activity was reported not to be required; on the contrary, inhibition of GSK3b activity stabilized its association with p53 (Watcharasit et al., 2003) . As Ser-9 phosphorylation of GSK3b inhibits its activity, this phosphorylation helps GSK3b associate with p53, according to these authors' theory, although many other factors regulating the formation of protein complexes should be further elucidated.
In this study, we also demonstrated that PKC may be an upstream target of triptolide to affect GSK3b function. As Go¨6976, an inhibitor of classical PKCa/b, attenuated the effect of triptolide, classical PKCs were considered upstream targets. Generally, changes in the balance of PKC activity have a close relation to various cellular processes such as proliferation, differentiation, apoptosis, migration or tumorigenesis (Koivunen et al., 2004) . Among PKCs, classical PKCa/bI have been linked to increased cell growth (Mandil et al., 2001; Jiang et al., 2004) . In urothelial cancers, not only the Triptolide-mediated enhancement of CDDP cytotoxicity Y Matsui et al expression but also the activity of PKCa/bI has been reported to increase, particularly in the most proliferative areas of the tumor (Aaltonen et al., 2006) . Our results showed that, compared with normal urothelium, cancer cells showed hyperphosphorylation of PKCs by CDDP/triptolide combined therapy, leading to the phosphorylation at Ser 9 of GSK3b. We consider that the difference in the response of PKC to triptolide between normal cells and cancer cells would be advantageous to promote CDDP-induced apoptosis in a cancer-specific manner. From our results in which p21 did not suppress immediately after drug exposure (Figure 1c) , triptolide may require multiple steps of signal activation or intracellular translocation of important molecules to modulate the PKC-GSK3b signaling pathway, which finally attenuated p53
Triptolide-mediated enhancement of CDDP cytotoxicity Y Matsui et al Figure 4 The interaction of GSK3b phosphorylated at serine 9 by PKC independently of 3-phosphoinositide-dependent protein kinase 1 activity is essential for the modulation of p53 transcriptional activity by triptolide. (a) Effect of the suppression of GSK3b expression on the synergic effect of triptolide and CDDP in RT112 cells shown by MTT assay (upper panel) and western blot analysis (lower panel). MTT assay shows the effect of GSK3b suppression on the susceptibility to CDDP and triptolide in RT112. A stable clone of RT112 transfected with pSUPER neo-gfp GSK3b vector containing shRNA targeting GSK3b were established (RT112 siGSK3b-6). RT112 siGSK3b-6 or RT112 mock (transfected by pSUPER vector) cells were then pretreated with or without 30 nM triptolide for 1 h followed by treatment with 30 mM CDDP for an additional 24 h. Cell viability was measured by MTT assay as average percent values±s.d. to cell viability of RT112 mock treated only by dimetyl sulfoxide (DMSO) used as vehicle from three independent experiments. Western blot analysis shows the influence of GSK3b suppression on the p53-p21-JNK proapoptotic pathway in RT112 cells. RT112 siGSK3b-6 or RT112 mock were treated by the indicated drugs for 12 h, and subjected to western blot analysis. (a) The change of subcutaneous RT112 tumor volume measured by photon emission in the in vivo imaging system. Nude mice bearing established subcutaneous tumors were grouped together to constitute similar mean tumor photon emissions in each group 6 days after the inoculation of RT112 cells expressing luciferase gene (day 0). Mice in each group were treated as described in 'Materials and methods,' and the effect of indicated drugs on tumor growth was measured by photon emission using the in vivo imaging system. (b) Histological examination of the effect of CDDP and triptolide on RT112 tumor in vivo. At day 16, the mice were killed, and the tumors were dissected. Morphological change was observed by hematoxilin-eosin (HE) stain, and the phosphorylation of JNK was examined by immunohistochemistry. Figure 5) and p-Ser 9 GSK3b was induced by triptolide in KK47 cells transfected with wild-type p53 (Supplementary Figure 6) , we also speculate that transcriptional activity-independent undetermined function of p53 may be required for triptolide to modulate the activity of the PKC-GSK3b signaling pathway. The detailed regulation mechanism of PKC activity other than 3-phosphoinositide-dependent protein kinase 1 stimulation should be further elucidated in the future.
To identify and characterize protein interaction under native conditions, 2D BN/SDS-PAGE, the combination of BN-PAGE and SDS-PAGE in a 2D approach, was a powerful tool (Camacho-Carvajal et al., 2004) . It was very helpful to detect the association of p53 with GSK3b in this study. It should be combined with other methods such as immunoprecipitation and immunocytochemistry to eliminate the possibility that each protein is part of separate complexes migrating at the same position in BN-PAGE. Furthermore, because the ratio of the complexes detected by 2D approach is different depending on the cells, treatments and detergent used, validation using other methods may be recommended in some cases. However, this method is suitable for highthroughput screening to identify MPCs in combination with liquid chromatography-tandem mass spectrometry (LC-MS/MS). In the future, this method will help us clarify the relationship between p53 and the PKCGSK3b axis, and resolve the dynamic change within cells falling into apoptosis.
To assess the clinical usefulness and safety, we used a subcutaneous xenograft model. In this model, triptolide was administered at 0.15 mg/kg four times per week. This dose was lower than those reported previously (Shamon et al., 1997; Fidler et al., 2003; Yang et al., 2003) and we could use safely without any remarkable adverse effects, but this low concentration could still enhance cancer-specific CDDP-induced cytotoxicity. When we consider clinical application of triptolide at a low concentration with chemotherapeutic agents to overcome its disadvantage, which is the narrow therapeutic window, a combination with CDDP, which is one of the most frequently used agents for urothelial cancer, is a very attractive choice.
In conclusion, we demonstrated that triptolide could promote CDDP-induced apoptosis in urothelial cancer cells with wild-type p53 by the suppression of p53-dependent p21 induction and that the modulation of p53 transcriptional activity with triptolide was mediated through the intranuclear association of p53 with GSK3b inactivated by PKC in cancer-specific manner. Compared with the use of peptides, small molecule inhibitors or antisense techniques (Lam et al., 2003; Weiss et al., 2003) , we consider that triptoide may be a more convenient, realistic and attractive p21 attenuation method, because triptolide is a common drug and exhibits cancer-specific p21 attenuation. Furthermore, this synergic effect of triptolide was not limited within urothelium or CDDP treatment. We are convinced that p21 target therapy using triptolide will develop as a promising clinical strategy applied to a broad spectrum of cancer treatments in the near future.
Materials and methods

Antibodies and reagents
Antibodies were obtained as follows: anticaspase-3, anticaspase-8 and anticytochrome c from BD PharMingen (San Diego, CA, USA), anti-PUMA from Sigma (St Louis, MO, USA) and anti-p53 (Ab-2) from Calbiochem (San Diego, CA, USA), p21 and MDM2 from Santa Cruz (Santa Cruz, CA, USA), anti-acetyl p53 (Lys373 and 382) from Upstate (Lake Placid, NY, USA) and anti-actin b from Abcam (Cambridge MA, USA). Other antibodies from Cell Signaling Technology (Beverly, MA, USA). Triptolide, Bax Channel Blocker ((±)-1-(3,6-Dibromocarbazol-9-yl)-3-piperazin-1-ylpropan-2-ol, bis TFA), LY294002, GF109203x, Go¨6983 and Go¨6976 were obtained from Calbiochem. SP600125 was obtained from Tocris Cookson Ltd. (Bristol, UK), and Cis-diamminedichloroplatinum (cisplatin, CDDP) was from WAKO (Osaka, Japan).
Cell culture
Human normal urothelial cells, six urothelial cancer cell lines (RT112, RT4, KK47, TCCsup, EJ and J82) and PC3 prostate cancer cell line were used for this study. Sequencing analysis and genotyping of p53 confirmed that RT112, RT4 and KK47 had wild-type p53 whereas four other cell lines harbored mutant p53. Five bladder cancer cell lines (RT112, KK47, TCCsup, EJ and J82) and PC3 were maintained in an RPMI1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. RT4 cells were in McCoy 5A. HNU cells were isolated from surgical specimens of patients with benign conditions (Southgate et al., 1994) . HNU cells were maintained in a keratinocyte serum-free medium and used for experiments in the second passage. Cells were incubated at 37 1C in a humidified atmosphere containing 5% CO 2 .
Plasmid and transfection pCMV-neo was a gift from Dr K Cho (University of Michigan Medical School). P53DN mutants containing one missense mutation at codon 135 (TGC-TAC), which were purchased from BD Bioscience, were ligated into pCMVneo. psiRNAh7SKhp21 vector containing shRNA targeting p21 was purchased from Invivogen (San Diego, CA, USA). pcDNA3 flag-p53 was a gift from Dr. Shimotohno (Institute for Virus Research, Kyoto University). pcDNA3 GSK3b, expressing wild-type GSK3b, pcDNA3 flag-GSK3b(S9A), expressing constitutively active mutant GSK3b (serine 9 was replaced with an alanine), and pSUPER neo-gfp GSK3b vector containing shRNA targeting GSK3b, were gifts from Dr Blattner (Institute for Toxicology and Genetics, Forschungszentrum Karlsruhe, Germany) (Kulikov et al., 2005) . Cells were transfected with the indicated vectors by using Lipofectamine 2000 (Life Technologies Inc., Grand Irand, NY, USA) following the manufacturer's instructions. Stable transfectants were selected by appropriate selection antibiotics, and were confirmed by sequencing, RT-PCR or western blot analysis.
Cell viability assay and detection of apoptosis Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay as described previously (Watanabe et al., 2006) . To detect apoptosis, nuclear staining was performed. For nuclear staining, cells were stained with 1 mM Hoechst 33342 solution (Wako, Osaka, Japan), and analysed with a fluorescence microscope. Apoptotic cells were identified by morphology and by condensation and fragmentation of their nuclei. The percentage of apoptotic cells was calculated as the ratio of apoptotic cells to total cells counted.
RNA isolation, RT-PCR and Real-time quantitative RT-PCR Total RNA preparation and first-strand cDNA synthesis was performed as described previously (Matsui et al., 2007) . Primer sequences used for cDNA amplification were as follows: p21 sense 5 0 -ATTAGCAGCGGAACAAGGAGTCAGACAT-3 0 and antisense 5 0 -CTGTGAAAGACAGAACAGTACAG GGT-3 0 ; MDM2 sense 5 0 -AATCATCGGACTCAGGTAC A-3 0 and antisense 5 0 -GTCAGCTAAGGAAATTTCAGG-3 0 ; PUMA sense 5 0 -CCAAACGTGACCACTAGCCT-3 0 and antisense 5 0 -ACAGGATTCACAGTCTGGGC-3 0 . Primers for amplification of the housekeeping gene, human GAPDH, were sense 5 0 -CGAGCCACATCGCTCAGACA-3 0 , and antisense 5 0 -TGAGGCTGTTGTCATACTTCTC-3. The RT-PCR exponential phase was determined to allow semiquantitative comparisons. PCR products were separated by electrophoresis on 2% agarose gels. Quantitative real-time PCR with SYBRgreen PCR Master Mix (Applied Biosystems, Foster City, CA, USA) was performed using the Gene Amp 5700 Sequence Detection System (Applied Biosystems) with the relative standard curve method.
Immunoblotting and immunoprecipitation
After drug treatments, cells were collected and lysed as described previously (Matsui et al., 2007) . Thirty to 50 micrograms of protein samples were separated by SDS-PAGE and transferred onto a polyvinylidene difluoride membrane following standard methods. Membranes were probed with appropriate dilutions of primary antibodies followed by incubation with horseradish peroxidase-conjugated secondary antibodies. After extensive washing, proteins were visualized by a chemiluminescent detection system (GE Healthcare, Buckinghamshire, UK).
For immunoprecipitation, cells were washed with phosphate-buffered saline and lysed in an appropriate volume of ice-cold lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% Nonidet P-40, containing 1 mM Na3VO4, 1 mM NaF, 1 mM phenylmethylsulfonyl fluoride and protease inhibitor cocktail tablets). The lysates were incubated with the indicated antibodies for 1 h to overnight after preclearance with protein G-Sepharose beads for 30 min. Subsequently, they were incubated with protein G-Sepharose beads for 1 h. Beadbound proteins were eluted by boiling for 5 min and subjected to immunoblot analysis.
Immunocytochemical studies RT112 cells were grown and treated with 30 mM CDDP with or without 30 nM triptolide for 12 h in chamber slides. For permeabilization and fixation, cells were treated with methanol at À20 1C for 10 min. Cells were washed and blocked with 10% serum containing phosphate-buffered saline, and then the primary antibody was added. Finally, fluorescein isothiocyanate-conjugated or tetramethylrhodamine isothiocyanate-conjugated secondary antibody was added, and cells were visualized using a Nikon Eclipse E1000 (Nikkon, Tokyo, Japan) and photographed with a DC300FX digital camera and IM1000 software (Leica Microsystems Digital Imaging, Cambridge, UK).
2D blue-native (BN)/SDS-PAGE 2D BN/SDS-PAGE was performed generally according to the protocol described previously (Camacho-Carvajal et al., 2004) . Briefly, RT112 cells preserved in À80 1C after drug treatment were lysed in appropriate lysis buffer and centrifuged at 15 000 g at 4 1C for 20 min, and the supernatant was used for BN-PAGE. BN gels were prepared as described (Camacho-Carvajal et al., 2004) and were run overnight at 4 1C. Next, for further separation in 2D SDS-PAGE, the lanes from first-dimension BN-PAGE were placed in 2D SDS-PAGE of the same thickness and overlaid with 1xSDS Laemmli loading buffer. The 2D run and immunoblotting were performed according to the standard protocols.
Mouse xenograft model RT112 stably transfected with the pCAGGS-luc vector containing the luciferase gene was established (Niwa et al., 1991) . To produce a subcutaneous xenograft model, tumor cells (5 Â 10 6 ) were injected into the subcutaneous tissue of pathogen-free 6-week-old BALB/cAJcl-nu/nu mice (Nihon Clea, Japan). After growing for 6 days, mice with tumor xenografts were divided into four groups (4 mice per group) and treated as follows: (a) vehicle alone (phosphate-buffered saline); (b) CDDP at 6 mg/kg weekly; (c) Triptolide at 0.15 mg/ kg four times per week; (d) combination of (b) and (c). The doses and injection regimens for these drugs were based on reports published previously (Fidler et al., 2003; Yang et al., 2003) . Sixteen days later, the mice were killed, and the tumors were dissected. Tumor growth patterns were measured twice a week on the basis of the photons emitted from luciferaseexpressing cells counted using the light-light chamber of a CCD camera system (Xenogen, Alameda, CA, USA) (Nogawa et al., 2005) . Approval for these studies was obtained from the Animal Research Committee of Graduate School of Medicine, Kyoto University.
